- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
“The performance of NGAL in these and other clinical studies appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, suggesting that we will likely see rapid expansion of its use in the coming years.”
Pumpa (Medicoinvestor Investigator Extraordinaire) found this interesting article:
In a paper from 2 Canandian Docteurs at the Hópital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, Quebec the status of AKI is reviewed. The development in myocardial infarction and non-development in therapies for AKI are discussed. quote:
When comparing the progress in the diagnosic tools available for AKI to that of myocardial infarction, the state-of-the-art is lagging significantly. Fifty years ago creatinine kinase (CK) was the only available marker for cardiac injury, as was serum creatinine for renal injury. In current practice, cardiac injury is identified through several laboratory tests, such as levels CK-MB, Troponin-I, Troponin-T, Myoglobin, and BNP. However, creatinine is still the only biomarker routinely used to identify kidney injury.
unquote:
the various Biomarkers are discussed- NGAL, Cystatin C, KIM-1, IL-18, L-FABP, NGAL emerges as the winner, the others might be good supplements. In short – the canadian doctors do not see NGAL as THE only relevant Biomarker, but certainly the most investigated one… Although they are probably right, there can be specific situations where the other markers equals or outperformes NGAL – I am convinced that BioPorto via the NGAL Test will get the Lions share of the market – where the other promising markers will be used as additional tests. When mentioning NGAL – this is the central phrase:
The performance of NGAL in these and other clinical studies appears sufficient to recommend its inclusion in an early diagnostic panel for AKI, suggesting that we will likely see rapid expansion of its use in the coming years.
Please use some time on this yourself:
About Stengaard
BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂
Related posts:
- 2014 – a threat for Bioporto, the NGAL-patent or the NGAL-test ?? Uncertainty about consequences of the recent decision by the European...
- “The NGAL Test” on Beckman Coulter AU 5822 Acording to an article printed in Clinical Chemistry and Laboratory Medicine an...
- The NGAL Test at Hvidovre Hospital Symposium about NGAL at Hvidovre Hospital, Copenhagen Senior Consultant and...
One Response to Rapid expansion of NGAL test in coming years
Leave a Reply Cancel reply
Ongoing debate
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
[…] Rapid expansion of NGAL test in coming years […]